THERAPY DOSSIER · th-6b69b172b230

Camostat mesilate

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL85164 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Camostat mesilate; Camostat mesylate; Camostat methanesulfonate
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04455815 ↗PHASE2terminated

A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.

COVID-19 Infection

Enrolment: 34 · Results not recorded

NCT04353284 ↗PHASE2completed

The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients (Phase IIa)

COVID-19

Enrolment: 70 · Results not recorded

NCT04524663 ↗PHASE2completed

A Phase 2 Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19

Covid19

Enrolment: 49 · Results not recorded

NCT04625114 ↗PHASE2terminated

The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

Covid19

Enrolment: 108 · Results not recorded

NCT04681430 ↗PHASE2completed

Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

Corona Virus Infection · SARS-CoV-2 Infection

Enrolment: 22 · Results not recorded

NCT04652765 ↗PHASE1terminated

COMBO Trial: Camostat With Bicalutamide for COVID-19

Covid19 · SARS-CoV Infection · Coronavirus Infection

Enrolment: 6 · Results not recorded

NCT04782505 ↗PHASE1completed

A Phase 1 Study to Compare and Evaluate the Safety and Pharmacokinetics According to the Dose of Camostat Mesylate in Healthy Volunteers

Healthy

Enrolment: 61 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27773435 ↗2016Reported benefit

A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.

RatOtherSprague-Dawleymale

Model: aldosterone and salt-induced kidney injury in rats, with corroborating in vitro studies in rat renal fibroblast cells

Camostat mesilate inhibited plasmin protease activity and suppressed plasmin-induced pro-fibrotic and inflammatory gene expression in renal fibroblasts, and ameliorated glomerulosclerosis and interstitial fibrosis in aldosterone and salt-treated rat kidneys.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…